drugset / Trial / NCT07315113
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
NaSequentialOpen-labelTreatment
Summary
This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
Timeline
- Start
- 2025-12-18
- Primary completion
- 2026-12
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NXP900 | Small molecule | — | Oral |
| Subject | Osimertinib | Small molecule | — | Oral |